Corcept Therapeutics (CORT) Peer Comparison
$116.10
$-2.41
(-2.03%)
As on 25-Sep-2026 16:00EDT
Market cap
$12,550 Mln
Revenue (TTM)
$831 Mln
P/E Ratio
258
P/B Ratio
18
Div. Yield
0 %
Edit
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
12,550 | 12,818 | 11,361 | 12,122 | 10,219 |
Revenue ($ Mln) |
831 | 692 | 5,020 | 432 | 777 |
Net Profit ($ Mln) |
54.90 | -696.24 | -199.00 | -136.72 | -191.64 |
Net Margin (%) |
6.61 | -100.64 | -3.96 | -31.66 | -24.68 |
RoE (%) |
8.11 | -- | -3.03 | -30.32 | -223.36 |
Price to Earnings |
258.00 | -- | -- | -- | -- |
Price-To-Book |
18.00 | 123.68 | 1.73 | 23.58 | 121.64 |
Income Statement ($ Mln)
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
830.81 | 691.84 | 5,020.00 | 431.80 | 776.57 |
|
Cost of Revenue
|
14.09 | 47.45 | 2,380.00 | 207.41 | 52.53 |
|
Gross Profit
|
748.43 | 473.81 | 2,050.00 | 191.00 | 591.02 |
|
Operating Expenses
|
810.32 | 1,187.86 | 2,178.00 | 362.16 | 912.58 |
|
Operating Profit (EBIT)
|
6.41 | -543.47 | 462.00 | -137.77 | -188.54 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
26.37 | -706.17 | -166.00 | -135.85 | -191.09 |
|
Provision for Tax
|
-35.26 | -7.73 | 33.00 | 0.24 | 0.56 |
|
Profit after Tax (Net Income)
|
54.90 | -696.24 | -199.00 | -136.72 | -191.64 |
|
Minority Interest
|
0.00 | 10.15 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
705.78 | -2,515.22 | 6,588.00 | 445.74 | 83.30 |
|
Minority Interest
|
0.00 | 10.15 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
29.12 | 2,832.54 | 5,121.00 | 106.44 | 217.70 |
|
Current Liabilities
|
153.80 | 890.65 | 1,852.00 | 120.26 | 460.45 |
|
Total Liabilities
|
836.65 | 936.03 | 13,358.00 | 641.86 | 689.81 |
Assets ($ Mln)
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
449.03 | 124.16 | 9,764.00 | 351.14 | 104.88 |
|
Current Assets
|
439.68 | 1,093.14 | 3,797.00 | 321.30 | 656.57 |
|
Total Assets
|
836.65 | 936.03 | 13,358.00 | 641.86 | 689.81 |
|
Total Debt*
|
9.42 | 2,493.78 | 3,918.00 | 93.59 | 219.21 |
|
Net Current Assets
|
285.87 | 202.49 | 1,945.00 | 201.04 | 196.12 |
Cashflow ($ Mln)
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
142.00 | -445.91 | 560.00 | -47.63 | -93.41 |
|
Cash Flow from Investing Activities
|
69.76 | -24.49 | -279.00 | -24.76 | -0.48 |
|
Cash from Financing Activities
|
-220.37 | 359.29 | -275.00 | 28.54 | 101.47 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
14.87 | -159.44 | -2.21 | -13.30 | -63.21 |
|
ROE (%)
|
8.11 | 41.15 | -3.03 | -30.32 | -223.36 |
|
ROA (%)
|
5.52 | -41.39 | -1.30 | -17.95 | -17.39 |
|
EBIT Margin (%)
|
3.17 | -89.09 | 1.61 | -30.84 | -17.57 |
|
Net Margin (%)
|
6.61 | -100.64 | -3.96 | -31.66 | -24.68 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
16.02 | 193.38 | 11.95 | 19.19 | 56.87 |
|
EBIT Growth (%)
|
-79.11 | 5.05 | -90.61 | -57.38 | 42.45 |
|
Net Profit Growth (%)
|
-58.66 | 10.33 | -145.85 | -60.49 | 22.38 |
|
EPS Growth (%)
|
-62.44 | 12.58 | -146.42 | -52.59 | 25.75 |
|
Book Value Growth (%)
|
12.98 | -36.90 | -3.87 | -8.64 | 9.44 |
Valuation Ratios
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
41.86 | -20.69 | -48.47 | -21.89 | -50.48 |
|
Price / Book Value
|
18.00 | 123.68 | 1.72 | 23.58 | 121.64 |
|
Dividend Yield (%)
|
0.00 | 0.00 | -- | 0.00 | 0.00 |
|
EV/EBITDA
|
423.22 | -24.82 | 21.77 | -111.58 | -56.38 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | -0.77 | 0.58 | 0.00 | 1.42 |
|
Short term debt to equity ratio
|
0.00 | -0.22 | 0.01 | 0.02 | 0.85 |
|
Current Ratio
|
2.86 | 1.23 | 2.05 | 2.67 | 1.43 |
|
Quick Ratio
|
2.77 | 1.17 | 1.10 | 2.38 | 1.34 |
|
Interest Coverage
|
-- | -6.86 | 0.36 | -- | -37.09 |
Operating Efficiency Ratios
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
9.26 | 36.78 | 22.95 | 15.23 | 35.73 |
|
Asset Turnover
|
0.84 | 0.41 | 0.33 | 0.57 | 0.70 |
|
Receivable days
|
28.27 | 52.44 | 70.73 | 44.72 | 104.82 |
|
Inventory Days
|
355.76 | 172.81 | 226.89 | 51.56 | 167.98 |
|
Payable days
|
785.55 | 296.14 | 45.50 | 12.52 | 529.03 |
|
Cash Conversion Cycle
|
-401.52 | -70.89 | 252.12 | 83.76 | -256.23 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
